Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: The vascular basis for the treatment of myocardial ischemia study

Circulation

Volumn 111, Issue 14, 2005, Pages 1747-1755

  Stone, Peter H ^a   Lloyd Jones, Donald M ^b   Kinlay, Scott ^a   Frei, Balz ^f   Carlson, William ^a   Rubenstein, Joel ^d   Andrews, Thomas C ^e   Johnstone, Michael ^c   Sopko, George ^g   Cole, Holly ^a   Orav, John ^a   Selwyn, Andrew P ^a   Creager, Mark A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NEWTON WELLESLEY HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f OREGON STATE UNIVERSITY   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Antioxidants; Cholesterol; Coronary disease; Exercise; Vasoconstriction

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; MEVINOLIN;

ADULT; AGED; AMBULATORY MONITORING; ANGINA PECTORIS; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STATISTICAL SIGNIFICANCE; TREADMILL EXERCISE; TREATMENT OUTCOME;

ANGINA PECTORIS; ANTIOXIDANTS; ASCORBIC ACID; CORONARY ARTERIOSCLEROSIS; DIET THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS, LDL; MALE; MYOCARDIAL ISCHEMIA; PYRROLES; VASOMOTOR SYSTEM; VITAMIN E;

EID: 20244362361     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000160866.90148.76     Document Type: Article

References (37)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282:2340-2346.
2. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
3. Stone PH, Chaitman BR, Forman S, Andrews TC, Bittner V, Bourassa MG, Davies RF, Deanfield JE, Frishman W, Goldberg AD, MacCallum G, Ouyang P, Pepine CJ, Pratt CM, Sharaf B, Steingart R, Knatterud GL, Sopko G, Conti CR. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol. 1997;80:1395-1401.
4. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation. 1990;81:748-756.
5. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328.
6. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris: REGRESS Study Group. Circulation. 1996;94:1503-1505.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
8. Stone PH, Lloyd-Jones DM, Johnstone M, Carlson W, Rubenstein J. Creager M, Frei B, Sopko G, Clark ME, Maccallum G, Kinlay S, Orav J, Selwyn AP. Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics. Am Heart J. 2004;147:875-882.
9. Tamesis B, Stelken A, Byers S, Shaw L, Younis L, Miller DD, Chaitman BR. Comparison of the Asymptomatic Cardiac Ischemia Pilot and modified Asymptomatic Cardiac Ischemia Pilot versus Bruce and Cornell exercise protocols. Am J Cardiol. 1993;72:715-720.
10. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin invest. 1990;86:228-234.
11. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
12. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993;88:2541-2547.
13. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996;93:1647-1650.
14. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a): role of oxygen-derived radicals. Circulation. 1995;92:1582-1589.
15. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
16. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
17. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 1995;26:1615-1622.
18. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;93:1107-1113.
19. Eskurza I, Seals DR, DeSouza CA, Tanaka H. Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans. Am J Cardiol. 2001;88:1067-1069.
20. Tiefenbacher CP, Friedrich S, Bleeke T, Vahl C, Chen X, Niroomand F. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol. 2004;286;H1425-H1432.
21. Mostaza JM, Gomez MV, Gallardo F, Salazar ML, Martin-Jadraque R, Plaza-Celemin L, Gonzalez-Maqueda I, Martin-Jadraque L. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol. 2000;35:76-82.
22. Schwartz RG, Pearson TA, Kalaria VG, Mackin ML, Williford DJ, Awasthi A, Shah A, Rains A, Guido JJ. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol. 2003;42:600-610.
23. Gordon JB, Ganz P, Nabel EG, Fish RD, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 1989;83:1946-1952.
24. Angina pectoris: pathophysiology, evaluation, and treatment. Ann Intern Med. 1971;75:263-296.
25. Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, Werns S, Kern M, Plotkin D, Shih WJ, Mitchel Y, Ganz P. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102:846-851.
26. Cannon RO, 3rd. Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter? Circulation. 2000;102:820-822.
27. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation. 2003;107:926-928.
28. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
29. Kinlay S, Behrendt D, Fang JC, Delagrange D, Morrow J, Witztum JL, Rifai N, Selwyn AP, Creager MA, Ganz P. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol. 2004;43:629-634.
30. Gotto AM. Antioxidants, statins, and atherosclerosis. J Am Coll Cardiol. 2003;41:1205-1210.
31. Frei B. To C or not to C, that is the question! J Am Coll Cardiol. 2003;42:253-255.
32. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-1160.
33. Stein JH, Carlsson CM, Papcke-Benson K, Aeschlimann SE, Bodemer A, Carnes M, McBride PE. The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia. J Am Coll Cardiol. 2001;38: 1806-1813.
34. Shaw LJ, Peterson ED, Shaw LK, Kesler KL, DeLong ER, Harrell FE Jr, Muhlbaier LH, Mark DB. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998;98:1622-1630.
35. Nabel EG, Barry J, Rocco MB, Campbell S, Mead K, Fenton T, Orav EJ, Selwyn AP. Variability of transient myocardial ischemia in ambulatory patients with coronary artery disease. Circulation. 1988;78:60-67.
36. Celermajer DS, Spiegelhalter DJ, Deanfield M, Deanfield JE. Variability of episodic ST segment depression in chronic stable angina: implications for individual and group trials of therapeutic efficacy. J Am Coll Cardiol. 1994;23:66-73.
37. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Beider R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.